The 430-Basis-Point Gap: Growth Stall Clouding Guidance Credibility
Q2 PAT rose 15.7% YoY, but FY-2027 guidance requires 20%. The call reveals why the gap exists—and whether management's path to close it is credible.
₹308.3 Cr
+15.7% YoY
₹14 Cr
one-time benefit to earnings
~₹294 Cr
~14% YoY run-rate
20% PAT growth
H1 tracking 15.7%; gap widens H2 task
The headline beat whisper expectations, but it masks a material miss against guidance. Q2 delivered ₹308.3 Cr PAT, up 15.7% year-on-year. Management's FY-2027 guidance demands 20% full-year PAT growth. That 430-basis-point gap is not rounding error—it is the quarter's core tension. A ₹14 Cr ESOP charge inflates the reported number; backing it out leaves ~₹294 Cr organic PAT, or roughly 14% YoY growth. More telling: disbursement roared 22% YoY, but revenue growth lagged at 16.8% YoY, and quarter-on-quarter revenue growth slowed to just 5.5% despite the disbursement spike. That disconnect—strong volume, weak pricing—signals either asset mix deterioration or pricing pressure that management did not fully explain. On the call, the company reaffirmed all guidance without uplift despite H1 momentum. That conservative posture suggests execution headwinds or macro caution the OpEx did not articulate openly.
Where the quarter came from
20% AUM and 20% PAT growth for FY27
OverstatedH1 AUM at 18% YoY (₹32,643 Cr as of Sept 30); PAT at 15.7% YoY unadjusted. On current trajectory, full-year targets require H2 beat-back to 24%+ to recover.
22% disbursement growth in Q2
Supported₹2,577 Cr disbursement on cheque clearance basis; 22% YoY confirmed. Best metric on the call.
Spreads protected at 5.5%+ in rising rate environment
SupportedExit spread 5.73% at Sept 30; 75% floating assets enable pass-through as RBI hikes ripple. 23 bps above minimum target held.
Branch expansion 40-50 for FY27
At riskOnly 4-6 branches added per recent quarter. At that pace, total FY27 additions ~25—45% shortfall of target.
What shifted on this call
The street's verdict
The stock closed at ₹441.65 on 11 Nov 2026, down 21.55% from its all-time high of ₹563. It trades below both the 50-day moving average (₹449.94) and 200-day average (₹475.75), with RSI at 50.7—neutral territory, no capitulation signal yet. The selloff reflects institutional caution. FII shareholding fell 34 basis points to 5.79% in Q1 FY-2027, while DII added 78 basis points to 9.93%, suggesting foreign hesitation but domestic patience. At 21.55% below ATH, the stock is not screaming cheap—the valuation reflects pricing in of the guidance-miss and execution-risk narrative. That is an honest market verdict: not a panic, but a credibility test.
The bull-bear ledger
Disbursement 22% YoY. Growth narrative intact. Exceed 17-18% prior guidance; momentum real in rising rate environment.
Spreads defended at 5.73%; 75% floating rate assets. Rate pass-through mechanics working; 23 bps above 5.5% floor. AA+ rating opens new funding pools at tighter cost.
Portfolio quality stable: 1.34% GNPA, 99% collection efficiency. Credit discipline evident; underwriting standards tight. Strong through-cycle franchise signal.
PAT growth 15.7% trails 20% guidance by 430 bps. H2 would need 24%+ to hit FY27 target. On current inputs, credibility slipping.
Revenue growth 16.8% YoY; QoQ only 5.5% despite 22% disbursement growth. Disconnect signals pricing or asset mix headwinds. Margin compression not fully explained.
Stage 2 risk rising: 3.3% → 3.55% QoQ; credit cost 30 bps vs 25 bps guided. Acceleration risk if macro deteriorates. Provisions could eat deeper and pinch profitability faster.
Branch expansion 4-6 per quarter vs 40-50 target: 85% shortfall. Execution slippage on geographic diversification and H2 disbursement acceleration plan.
Cost of funds 7.7% elevated; ALCO decision (Dec 2026) pivotal. Further RBI rate hikes compress spreads faster than RPLR pass-through catches up. Margin reset risk.
ESOP charge ₹14 Cr masks organic softness. Adjusted PAT 14% vs 15.7% reported; earnings quality clouded by one-time benefit to the quarter.
Ranked risks: what should concern a holder most
PAT growth guidance miss widens in H2
HIGHH1 PAT at 15.7% vs 20% target leaves H2 needing 24%+ to recover. If H2 stays at 15-16%, FY27 target officially breaks. Guidance credibility erodes and stock likely re-rates down 10-15%.
Stage 2 / credit cost spiral accelerates
MEDIUM-HIGHGS2 rose 25 bps in one quarter. If macro deteriorates further or deferrals roll into Stage 3, provisions could accelerate faster than expected. Credit cost already at 30 bps vs 25 bps guided; overshoot on annual target possible. ROA/ROE compression follows.
Branch expansion execution slips further
MEDIUMOnly 4-6 branches per quarter vs 40-50 target. If pace remains flat, H2 disbursement growth at risk of missing 20%+, widening the PAT gap. Geographic diversification into Tier 2-3 also delayed.
Margin compression from elevated cost of funds
MEDIUMCost at 7.7%, RPLR pass-through lags 90 days. If ALCO in Dec stays hawkish and rate hikes continue, spread expansion stalls and ROE targets (17% in 2-3 years) slip. 5.73% exit spread may be peak.
Macro slowdown crimp disbursement momentum
MEDIUMRBI rate hikes (25 bps to 5.5%) may slow borrower demand in price-sensitive Tier 2-3 segments. Semi-urban portfolio (55% salaried, 45% informal income) exposed to El Niño, drought. Demand volatility higher than expected.
The debate
What to watch next
1 · Q3 PAT growth run-rate—make-or-break for guidance
Q3 FY-2027 PAT growth must accelerate to 18%+ YoY for the 20% full-year target to remain credible. If it sticks at 15-16%, the guidance functionally breaks and the stock is likely to re-rate down 10-15% as a credibility penalty.
2 · Branch expansion pace and Q3 disbursement momentum
Monitor Q3 branch additions and disbursement growth. If branches stay at 4-6 per quarter and disbursement slows below 20% YoY, the execution risk on all growth targets materializes and H2 becomes a miss.
3 · ALCO rate decision (December 2026) and margin reset
RBI's next monetary policy will determine whether cost of funds stabilizes or rises further. If RBI stays on hold, margin compression slows and spreads hold. If it hikes, cost of funds rises and spread expansion stalls; FY27 ROE targets slip.
This was a steady quarter, not a step-change. Aadhar executed on disbursement (22% YoY) and defended spreads (5.73%), but the bottom-line growth (15.7% PAT YoY) missed guidance (20%) by 430 basis points, and branch expansion (4 additions vs 40-50 target) flagged execution slippage. The stock's 21.55% drawdown from all-time-high is justified, not overblown.
The number to track from here is Q3 PAT growth. If it bounces to 18%+ and Stage 2 stabilizes, the bull case regains credibility and the stock can re-rate toward ₹475-490. If it stays at 15-16%, the 20% FY-2027 target becomes a miss, the bear case hardens, and the stock likely tests ₹410-420. That is the call on the table.
Informational and educational content only. Not investment advice.